Calidi Biotherapeutics to Showcase RedTail Platform's Potential in Solid Tumors at AACR-IO 2026
Event summary
- Calidi Biotherapeutics will present data on its RedTail platform's novel approach to Bispecific T-Cell Engagers (BiTEs) at the 2026 AACR-IO Conference in Los Angeles, February 18-21.
- RedTail is designed to target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads.
- CLD-401, the lead candidate from the RedTail platform, is engineered to express high levels of IL-15 superagonist in the TME.
- Calidi anticipates submitting an Investigational New Drug (IND) application for CLD-401 by the end of 2026.
The big picture
Calidi Biotherapeutics is positioning its RedTail platform as a potential game-changer in the delivery of genetic medicines to solid tumors, an area where traditional BiTEs have struggled. The company's focus on remodeling the tumor microenvironment and enabling high-level expression of therapeutic payloads could address a significant unmet need in oncology. The upcoming presentation at the AACR-IO Conference will be a key milestone in validating the platform's potential.
What we're watching
- Clinical Development
- The pace at which Calidi advances CLD-401 through IND-enabling studies and potential approval.
- Strategic Partnerships
- Whether Calidi can secure partnerships to accelerate the RedTail platform's clinical development.
- Market Differentiation
- How RedTail's ability to deliver complex biologics directly within the tumor microenvironment will position Calidi against competitors in the immuno-oncology space.
Related topics